论文部分内容阅读
目的探讨厄洛替尼(Erlotinib)联合细胞因子诱导的杀伤细胞(CIK)生物免疫治疗晚期肺腺癌的临床效果。方法选取2013年1月至2014年2月间经病理学或细胞学检查确诊的一线治疗失败的100例晚期(ⅢB期~Ⅳ期)肺腺癌患者,随机分为试验组和对照组,每组50例。试验组患者采用厄洛替尼和CIK生物免疫治疗,对照组患者采用厄洛替尼单药治疗,评价两组患者无进展生存(PFS)时间和不良反应发生情况。结果试验组和对照组患者的PFS分别为6.3个月(95%CI:6.0~6.6)和4.4个月(95%CI:4.2~4.6),差异有统计学意义(P<0.05)。两组患者的不良反应主要为皮疹和腹泻。试验组患者在CIK输注过程中有2例出现胸闷,5例出现乏力,6例出现发热。结论厄洛替尼联合CIK治疗晚期肺腺癌是一种安全有效的方法。
Objective To investigate the clinical effect of erlotinib combined with cytokine-induced killer (CIK) biological immunotherapy on advanced lung adenocarcinoma. Methods One hundred patients with advanced lung adenocarcinoma (stage ⅢB-Ⅳ) who had failed first-line treatment diagnosed by pathology or cytology from January 2013 to February 2014 were randomly divided into test group and control group, Group of 50 cases. The patients in the experimental group received erlotinib and CIK bioimmunotherapy while the control group received erlotinib monotherapy. The progression-free survival (PFS) and adverse reactions in both groups were evaluated. Results The PFS of trial group and control group were 6.3 months (95% CI: 6.0-6.6) and 4.4 months (95% CI: 4.2-4.6), respectively. The difference was statistically significant (P <0.05). Adverse reactions in both groups were mainly rash and diarrhea. Patients in the test group had chest tightness in 2 cases during CIK infusion, fatigue in 5 cases and fever in 6 cases. Conclusion erlotinib combined with CIK in the treatment of advanced lung adenocarcinoma is a safe and effective method.